BAGNOL CONSULTING

BAGNOL CONSULTING provides expertise in preclinical drug discovery through onsite training, study evaluation and validation.
• Target identification and validation in various tissues and therapeutic areas.
• Projects evaluation and target portfolio management.
• In vivo pharmacology assays development, translational disease models validation for proof of concept or mechanism of action studies.
• Histology and tissues processing, immunohistochemistry, in situ hybridization, single labeling or multiplexing for cellular expression studies, determination of biological pathways and mechanistic hypothesis generation. Digital microscopy analysis.
• Autoradiography and biomarker ID for receptor occupancy and/or target engagement studies.
• Human biological specimen’s procurement, processing for reverse translational studies. Human and rodent neuroanatomy.
• CROs and external collaborations management.
• Business development, in-licensing opportunities sourcing and evaluation, competitive intelligence and partnership support.

Didier Bagnol is a Ph.D. level scientist with training in neuroscience and physiology with 20 year’s R&D expertise in the pharmaceutical industry and academia. From February 2001 to August 2016, Dr Bagnol was a research director at Arena Pharmaceuticals Inc. - a biopharmaceutical company based in US, specialized in small molecule drug discovery for G protein-coupled receptors. Dr Bagnol initiated and led several preclinical drug discovery programs from idea generation to late lead compound identification and participated in the nomination of several clinical candidates which led to IND filing one of which was approved by the FDA in 2012. Didier’s effort in establishing and managing cellular imaging and histology research core laboratories was instrumental for the identification of novel and innovative drug targets. He developed proven abilities to set up in vivo pharmacology and translational animal models for target validation, lead compound identification and optimization, proof of principle and mechanism of action studies. Through these various activities Didier has gained broad expertise across all phases of drug discovery and early development in various therapeutic areas such as neuroscience, endocrinology, metabolic diseases, diabetes, gastroenterology and inflammation. During his tenure at Arena, Didier participation helped to establish the success of numerous partnerships with pharmaceuticals companies like Eli-Lilly, Johnson & Johnson, Boerhinger-Ingelheim. He established and managed critical external collaborations with leading team in academia or carefully selected contract research organizations with relevant expertise. Prior to join Arena, Didier was a tenured Associate Professor at Aix-Marseille University, France and a research fellow at the Molecular and behavioral Neuroscience Institute, University of Michigan, Medical School, Ann Arbor. He authored numerous peer review publications and is an inventor on several patents.

Publications

• J. Leprince, D. Bagnol, R. Bureau, S. Fukusumi, R. Granata, S. Hinuma, D. Larhammar, S. Primeaux, J. Sopkova-de Oliveiras Santos, K. Tsutsui, K. Ukena, H. Vaudry. The Arg-Phe-amide peptide 26RFa/QRFP and its Receptor. IUPHAR Review. Br. J. Pharmacol. (2017) doi: 10.1111/bph.13907 e-print.
• D. Bagnol, H. A. Al-Shamma, D. Behan, K. Whelan and A. J. Grottick; Diet Induced Models of Obesity. Current Protocol in Neuroscience (2012) Chap 9: Unit 9.38.
• Darleen Sandoval, Didier Bagnol, Stephen C. Woods, David D’Alessio, Randy J. Seeley, Arcuate GLP-1 receptors regulate glucose homeostasis but not food intake. Diabetes (2008) 57(8): 2046-2054.
• Zhi-Liang Chu, Chris Carroll, Jean Alfonso, Veronica Gutierrez, Hongmei He, Annette Lucman, Melinda Pedraza, Helen Mondala, Didier Bagnol, Ruoping Chen, Robert M. Jones, Dominic P. Behan and James Leonard, A Role for Intestinal Endocrine Cell-Expressed GPR119 in Glycemic Control by Enhancing GLP-1 and GIP Release Endocrinology (2008) 149(5): 2038-2047.
• Zhi-Liang Chu, Robert M. Jones, Hongmei He, Chris Carroll, Veronica Gutierrez, Annette Lucman, Molly Moloney, Hui Gao, Helen Mondala, Didier Bagnol, David Unett, Yin Liang, Keith Demarest, Graeme Semple, Dominic P. Behan and James Leonard, A role for beta-Cell-Expressed GPR119/ GDIR in Glycemic Control by Enhancing Glucose-Dependent Insulin Release. Endocrinology (2007), 148 (6):2601-2609.
• J.Kampe, P.Wiedmer, P.T.Pfluger, T.R.Castaneda, L.Burget, H.Mondala, J.Kerr, C. Liaw, B.J.Oldfield, M.H.Tschöp, D.Bagnol, Effect of central administration of QRFP(26) peptide on energy balance and characterization of a second QRFP receptor in rat. Brain Research (2006), 1119:113-149
• A. Grottick , D. Bagnol, S. Phillips, J. Mc Donald, D. P. Behan, D. Chalmers and Y. Hakak. Neurotransmission- and cellular stress-related gene expression associated with prepulse inhibition in mice. Mol Brain Research (2005) vol 139: 153-162.
• D. Bagnol. G protein-coupled receptors expression in hypothalamic circuits involved in metabolic diseases. Current Opinion in Drug Discovery and Development, (2004) vol 7: 665-682.
• T. Takahashi, D. Bagnol, D. Schneider, Y. Mizuta, T. Ishiguchi, K. LePard, J. J. Galligan, S. J. Watson and C. Owyang. Orphanin FQ causes contractions via inhibiting purinergic pathway in the rat colon. Gastroenterology (2000) 119:1054-63.
• X. Y. Lu, D. Bagnol, S. Burke, H. Akil, S. J. Watson. Differential distribution and regulation of OX1 and OX2 Orexin/hypocretin receptors in the brain upon fasting. Hormones and behavior (2000) vol 37 : 335-344.